Jasmine Zain, MD, Oncology, Duarte, CA, City of Hope's Helford Clinical Research Hospital

JasmineZainMD

Oncology Duarte, CA

Hematologic Oncology

Director, T-cell Lymphoma Program

Dr. Zain is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Zain's full profile

Already have an account?

Education & Training

  • NYU School of Medicine
    NYU School of MedicineFellowship, Hematology, 1996 - 1999
  • NYU School of Medicine
    NYU School of MedicineFellowship, Medical Oncology, 1995 - 1997
  • NYU School of Medicine
    NYU School of MedicineFellowship, Hematology, 1994 - 1995
  • North Shore University HospitalResidency, Internal Medicine, 1989 - 1992
  • Fatima Jinnah Medical CollegeClass of 1987

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2021
  • CT State Medical License
    CT State Medical License 2001 - 2003
  • NY State Medical License
    NY State Medical License 1994 - 2021
  • NC State Medical License
    NC State Medical License 1992 - 2001
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
    Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
    Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
    Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • 6th Annual Conference On How The Experts Treat Hematologic Malignancies 
    City of Hope, Santa Monica, California - 9/18/2013

Press Mentions

  • City of Hope Doctors Present Research on First KRAS Inhibitor and CAR T Cell Therapy at ASCO
    City of Hope Doctors Present Research on First KRAS Inhibitor and CAR T Cell Therapy at ASCOMay 29th, 2019
  • City of Hope Clinical and Laboratory Investigators Present New Research at the 60
    City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018

Committees

  • Co-Chair, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2017 - Present
  • Member, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2016 - 2017

Professional Memberships

  • American Society of Hematology
    Member
  • American Society of Oncology
    Member
  • Member
  • American Society for Blood and Marrow Transplantation
    Member
  • International Society of Cutaneous Lymphoma
    Member
  • Southwest Oncology Group
    Member

Hospital Affiliations